Fort Washington, PA USA
Add to Favorites | Newsroom RSS | Share

Our News on Newswise

NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies

The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to facilitate studies of duvelisib in the treatment of hematologic malignancies.
9-Feb-2016 9:00 AM EST Add to Favorites

Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data

DrAnthonyBlau_Headshot.jpg

Thirty-two researchers from 14 institutions joined forces to identify personalized treatment options for a patient with metastatic triple-negative breast cancer.
27-Jan-2016 9:30 AM EST Add to Favorites

NCCN Publishes New Clinical Practice Guidelines for Vulvar Cancer

VulvarGuidelines22016_COVER.jpg

The new NCCN Guidelines for Vulvar Cancer are the most comprehensive and up-to-date clinical guidelines available to clinicians today.
26-Jan-2016 1:30 PM EST Add to Favorites

NCCN Awards Research Grants to Five Investigators to Study Effectiveness of Enzalutamide in Various Cancers

The NCCN Oncology Research Program has awarded five research grants to investigate the effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate cancers.
13-Jan-2016 9:00 AM EST Add to Favorites

NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies

The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies.
11-Jan-2016 8:00 AM EST Add to Favorites

NCCN Awarded $2 Million in Research Funding From Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers

The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.
6-Jan-2016 8:00 AM EST Add to Favorites

NCCN Collaborates with Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer

NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.
30-Nov-2015 10:30 AM EST Add to Favorites

NCCN Foundation® Appoints Three New Representatives to Board of Directors

SusanStein.jpg

The NCCN Foundation welcomes Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH, as the newest representatives to its Board of Directors.
20-Nov-2015 3:00 PM EST Add to Favorites

Our Experts on Newswise

Our experts are coming soon...

Our YouTube Videos